No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
113 |
4. Check minimum number of eventsNone |
113 |
5. Include endpoints |
135 |
6. Filter based on genotype QC (FinnGen only) |
119 |
Control definitions (FinnGen only)
- Control exclude
- E4_OBESITY_HYPER
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other hyperalimentation
based on the number of shared cases.
Similar with more cases:
- Obesity and other hyperalimentation
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 767 | 460 | 298 |
| Only index persons | 615 | 384 | 231 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.68 | 48.81 | 50.63 |
| Only index persons | 48.07 | 47.96 | 48.24 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 119 | 79 | 40 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | 52.36 | 48.89 | 59.22 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 123
- Matched controls
- 1230
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E68
ICD-10 Finland
Sequelae of hyperalimentation
+∞
76.1
65
*
E66.01
ICD-10 Finland
Obesity due to excess calories
22.4
47.3
39
25
E66.8
ICD-10 Finland
Other obesity
93.9
36.6
39
6
E66.00
ICD-10 Finland
Metabolic syndrome
23.3
20.3
29
16
E66.9
ICD-10 Finland
Obesity, unspecified
69.6
16.2
18
*
QBJ30
NOMESCO Finland
Correction of abdominal apron
+∞
16.0
15
*
E67.3
ICD-10 Finland
Hypervitaminosis D
+∞
16.0
15
*
JDF11
NOMESCO Finland
Laparoscopic gastric bypass
+∞
13.8
13
*
T82
ICPC
Obesity
18.4
12.6
19
12
103
Kela drug reimbursment
Diabetes, insulin-treated
3.7
11.0
49
185
SPAT1262
SPAT
Handing over of treatment supplies
4.4
10.6
32
91
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
+∞
10.6
10
*
E67.8
ICD-10 Finland
Other specified hyperalimentation
+∞
10.6
10
*
E67.2
ICD-10 Finland
Megavitamin-B6syndrome
+∞
9.5
9
*
27799
ICD-8 Finland
Obesity not specified as of endocrine origin
+∞
9.5
9
*
27899
ICD-8 Finland
Other hyperalimentation, Other and unspecified
+∞
9.5
9
*
N02AX02
ATC
tramadol; systemic, rectal
3.2
9.4
71
364
A10BA02
ATC
metformin; oral
3.3
9.3
49
203
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.5
9.1
42
160
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
12.9
8.8
15
13
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
8.6
52
232
310
Kela drug reimbursment
Orlistat, sibutramine and other major and expensive medicines used to treat obesity
96.4
8.5
9
*
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
3.8
7.5
26
81
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.1
7.4
41
172
J01FF01
ATC
clindamycin; systemic
3.0
7.3
46
207
G47.3
ICD-10 Finland
Sleep apnoea
3.1
7.3
40
167
C03CA01
ATC
furosemide; systemic
2.8
7.0
50
240
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
3.6
6.8
26
86
SPAT1215
SPAT
Assessment of need for medical rehabilitation
8.6
6.8
14
18
ZXD05
NOMESCO Finland
Urgent procedure
2.7
6.5
49
241
M04AA01
ATC
allopurinol; systemic
3.5
6.4
25
84
E66
ICD-10 Finland
Obesity
8.4
6.3
13
17
SPAT1229
SPAT
Assessment of need for aid
4.3
6.2
17
44
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
3.8
6.2
21
64
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
6.2
25
86
N06AB03
ATC
fluoxetine; oral
3.4
6.1
24
81
J01MA12
ATC
levofloxacin; systemic
2.9
6.1
36
155
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
84
456
3.66
10.52
5.4
4.4
35.18
36.09
g/l
0.56
76
429
58
253
3.45
10.30
2.8
2.0
3.00
3.00
mg/l
0.00
49
224
84
466
3.53
9.95
4.3
2.4
78.54
80.24
nmol/l
0.17
76
418
81
458
3.25
8.93
3.0
1.9
106.82
98.73
pmol/l
0.68
49
224
44
176
3.34
8.77
2.9
2.9
0.79
0.81
mmol/l
0.45
39
167
43
181
3.12
7.75
2.1
1.7
1128.48
1293.18
nmol/l
0.47
33
136
60
313
2.79
7.21
5.0
3.6
5.53
5.48
mg/mmol
0.01
35
191
45
213
2.75
6.39
2.0
1.7
494.97
472.99
pmol/l
0.11
37
178
64
373
2.49
5.82
3.2
3.3
2.32
2.36
mmol/l
1.42
57
348
79
517
2.48
5.44
10.7
6.7
1.20
1.22
mmol/l
0.92
69
435
12
26
5.00
4.18
2.5
2.3
25.50
24.16
mmol/l
0.38
12
26
72
487
2.15
4.15
3.4
2.7
—
—
estimate
—
0
0
53
323
2.13
3.96
2.3
1.6
20.91
21.84
nmol/l
0.16
43
274
19
73
2.90
3.85
1.7
1.6
—
—
—
0
0
70
485
2.03
3.60
4.5
3.0
107.93
102.85
ug/l
0.11
62
448
16
58
3.02
3.58
1.5
1.6
—
—
—
0
0
19
78
2.70
3.41
3.6
4.1
62.00
81.81
ng/l
0.75
12
67
43
254
2.07
3.40
1.8
1.7
0.84
1.46
mg/l
1.06
33
207
45
274
2.01
3.26
2.8
3.1
347.69
337.61
umol/l
0.18
36
242
102
830
2.34
3.21
11.3
8.6
84.10
77.45
u/l
1.04
102
783
9
20
4.77
3.18
1.2
1.1
—
—
—
0
0
47
298
1.93
2.99
4.4
2.9
0.14
0.45
e6/l
2.07
37
225
79
599
1.89
2.85
5.9
5.0
7.06
6.54
mmol/l
1.05
79
558
11
34
3.45
2.81
1.4
1.4
179.67
311.12
ug/g
—
6
19
48
314
1.87
2.74
3.2
3.2
897.00
1321.23
ng/l
0.69
37
268
6
10
6.24
2.73
1.0
1.5
—
—
—
0
0
28
155
2.04
2.57
2.4
1.9
29.32
29.31
s
0.01
28
149
5
7
7.38
2.57
1.4
1.6
0.06
-0.40
mmol/l
—
5
7
5
7
7.38
2.57
1.0
1.4
53.60
68.07
ng/l
—
5
7
5
7
7.38
2.57
1.2
1.4
151.00
89.29
pmol/l
—
5
7
39
245
1.87
2.49
2.8
2.5
—
—
—
0
0
44
289
1.81
2.43
1.3
1.2
0.68
1.24
u/ml
0.55
12
77
5
8
6.45
2.39
1.2
1.0
—
—
—
0
0
26
144
2.02
2.38
4.2
2.8
4.80
3.01
e6/l
0.24
13
73
8
25
3.35
2.13
5.0
1.9
9.69
5.27
pmol/l
—
8
25
96
815
1.81
1.98
5.6
4.5
14.78
14.83
pmol/l
0.05
85
749
77
616
1.67
1.97
9.7
10.7
4.57
4.01
e9/l
1.37
69
541
5
13
3.96
1.73
1.4
1.2
—
—
—
0
0
22
129
1.86
1.71
5.8
4.6
34.47
33.12
%
0.24
15
85
8
31
2.69
1.69
1.1
1.3
—
—
—
0
0
8
31
2.69
1.69
1.3
1.5
—
2.67
—
0
8
28
179
1.73
1.65
1.9
1.9
—
—
—
0
0
7
26
2.79
1.60
2.7
2.2
131.14
124.50
g/l
—
7
18
55
420
1.56
1.60
5.7
4.0
55.83
29.54
ng/l
0.46
43
287
7
27
2.69
1.54
1.6
1.3
—
—
—
0
0
9
38
2.47
1.49
1.7
1.2
—
—
—
0
0
9
38
2.47
1.49
1.7
1.2
—
—
—
0
0
15
81
1.97
1.48
2.0
3.1
29.89
4.68
ug/l
—
10
73
7
28
2.59
1.47
1.1
1.5
—
71.08
—
0
6
6
22
2.81
1.45
1.0
2.0
—
—
—
0
0
107
968
1.81
1.40
9.6
5.8
41.26
38.98
mmol/mol
1.50
97
913
11
54
2.14
1.37
1.3
1.2
—
—
—
0
0
69
573
1.47
1.26
4.2
4.1
0.00
0.00
estimate
-0.00
17
136
70
583
1.47
1.26
4.2
4.2
0.00
0.00
estimate
-0.00
20
129
12
64
1.97
1.23
5.0
6.5
24.32
25.78
mmol/l
0.66
12
64
69
577
1.45
1.19
4.1
4.2
0.00
0.00
estimate
-0.00
20
136
5
20
2.56
1.16
3.4
2.7
17.12
16.48
%
—
5
20
7
32
2.26
1.10
1.7
1.5
—
—
—
0
0
21
140
1.60
1.06
8.8
6.6
103.33
104.54
mmol/l
0.51
21
140
16
99
1.71
1.06
3.8
3.7
—
—
—
0
0
5
22
2.32
1.04
2.0
1.3
—
—
—
0
0
24
167
1.54
1.02
4.4
2.7
0.81
1.02
e6/l
0.22
11
94
29
211
1.49
1.01
1.8
1.7
—
—
—
0
0
6
28
2.20
0.93
1.2
2.2
—
—
—
0
0
6
29
2.12
0.90
1.3
1.8
—
—
—
0
0
11
64
1.79
0.89
1.6
1.4
—
—
—
0
0
6
31
1.98
0.85
1.3
1.8
—
—
—
0
0
42
338
1.37
0.84
3.6
3.4
0.00
0.00
estimate
-0.00
16
110
7
41
1.75
0.71
2.0
2.2
—
—
—
0
0
19
137
1.46
0.70
1.7
1.6
—
—
—
0
0
103
964
1.42
0.69
7.4
5.3
1.89
1.91
mu/l
0.06
95
888
89
819
1.31
0.64
6.0
4.3
16.79
10.67
mm/h
2.82
81
755
109
1036
1.46
0.61
27.6
15.7
27.03
21.50
mg/l
1.10
104
829
6
36
1.70
0.57
2.7
1.8
—
—
—
0
0
6
38
1.61
0.55
1.7
2.0
—
—
—
0
0
10
67
1.54
0.51
8.6
8.9
0.46
0.71
%
—
10
67
25
202
1.30
0.48
1.4
1.3
1.19
8.72
u/ml
—
7
82
7
48
1.49
0.47
1.7
2.1
—
—
—
0
0
102
970
1.30
0.46
5.5
4.1
1.49
1.24
mmol/l
1.32
90
899
51
452
1.22
0.46
2.0
1.9
1.71
1.35
mmol/l
1.20
40
378
8
55
1.49
0.44
1.5
1.3
21.44
22.35
iu/l
—
8
46
8
56
1.46
0.43
1.6
2.0
—
—
—
0
0
5
32
1.59
0.43
1.4
1.5
—
—
—
0
0
5
33
1.54
0.42
1.2
1.3
—
—
—
0
0
15
116
1.33
0.39
6.0
9.4
—
—
—
0
0
9
67
1.37
0.39
8.1
9.0
0.84
1.38
%
—
9
67
15
118
1.31
0.35
1.8
1.8
—
—
—
0
0
26
223
1.21
0.31
1.8
1.3
18.14
25.81
iu/ml
—
7
79
38
339
1.18
0.30
3.8
4.3
0.00
0.00
estimate
-0.00
18
128
103
1000
1.18
0.23
6.6
4.9
6.33
5.86
mmol/l
2.08
91
926
48
445
1.13
0.22
3.8
4.1
0.00
0.00
estimate
-0.00
16
112
23
202
1.17
0.22
3.8
3.5
599.56
136.37
ng/l
0.36
18
150
0
11
0.00
0.21
0.0
2.8
—
15.49
—
0
11
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.4
—
—
—
0
0
6
48
1.26
0.20
4.0
3.4
11.00
806.89
u/ml
—
6
40
0
14
0.00
0.20
0.0
5.4
—
130.57
—
0
14
15
173
0.85
0.18
1.1
1.4
—
—
—
0
0
15
129
1.19
0.18
1.9
1.9
—
—
—
0
0
15
130
1.18
0.16
1.7
1.8
—
—
—
0
0
104
1018
1.14
0.15
6.6
4.8
1.39
1.50
mmol/l
1.71
93
945
20
218
0.90
0.11
3.2
4.6
19.53
22.76
%
—
8
98
104
1023
1.11
0.10
6.5
4.9
4.49
4.66
mmol/l
1.00
93
953
5
45
1.12
0.10
1.6
1.4
333.20
304.30
mu/l
—
5
40
26
244
1.08
0.09
3.5
4.7
1.02
1.02
kg/l
0.19
20
155
6
58
1.04
0.08
1.0
1.1
—
—
—
0
0
87
882
0.95
0.05
28.8
18.8
13.91
13.60
%
1.44
87
873
18
170
1.07
0.04
2.7
3.0
0.77
0.72
ug/l
0.14
11
107
103
1038
0.95
0.02
7.3
5.5
2.52
2.72
mmol/l
1.68
91
963
67
677
0.98
0.01
3.5
3.2
—
—
—
0
0
112
1117
1.03
0.00
40.5
24.2
39.09
40.33
%
1.51
112
1103
112
1118
1.02
0.00
40.1
24.0
129.98
134.76
g/l
2.62
112
1104
8
88
0.90
0.00
1.7
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
7.89
—
0
8
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
22.88
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
54
0.92
-0.00
1.8
1.6
444.36
997.86
mu/l
—
5
46
0
5
0.00
-0.00
0.0
1.6
—
17.98
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
1.20
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.2
—
1.50
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERALI and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALI | 2.001 [1.3, 3.08] | 0.002 |
| Birth year | 0.997 [0.99, 1.01] | 0.458 |
During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 272 females with E4_HYPERALI died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALI | 3.536 [2.12, 5.89] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 172 males with E4_HYPERALI died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERALI.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.189% | 0.859% |
| 5 | 1.144% | 4.315% |
| 10 | 3.079% | 10.302% |
| 15 | 5.724% | 18.891% |
| 20 | 9.954% | 29.966% |
Relationships between endpoints
↥Index endpoint: E4_HYPERALI – Other hyperalimentation
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data